Drug intelligence / Profile preview

VYR-206

Development stage: Preclinical
Lead developer: Vyripharm Biopharmaceuticals
Modality: Small Molecules

Overview

VYR-206 is a **CB1 antagonist** developed by Vyripharm Biopharmaceuticals as a novel formulation derived from rimonabant, originally an obesity treatment, now repurposed for diagnostic and therapeutic applications. It integrates nuclear medicine imaging for theranostic use, targeting CB1 receptors to enable diagnosis and monitoring of neurological disorders and potentially treating cancers such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Vyripharm has collaborated with National Yang-Ming University on its diagnostic potential for neurological outcomes and with Regis Technologies for cGMP manufacturing.[1][2][4][5][7][8][10][14]

Other names: CB1 antagonist analogueCB-1 antagonist analogueCB 1 antagonist analoguerimonabant analogue

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on VYR-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-206.

Explore the full profile